23 February 2023
Scientists at Open Targets, EMBL’s European Bioinformatics Institute (EMBL-EBI), and GSK are revealing the shared basis of diseases using a map of interacting human proteins. By helping to understand how biological processes affect human traits and diseases, this work will prioritise new targets for drug discovery and identify drug repurposing opportunities.
Proteins are molecules that do most of the work in our cells and are made following blueprints encoded in genes. They are ess...
19 January 2023
Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.
A new library documenting hundreds of mutations can help to explain why some cancers don’t respond to immunotherapies, and highlights potential pathways that could be drug targets in the future.
The researchers, from the Wellcome Sanger Institute, Open Targets, and collaborators, used CRISPR gene editing technology and mini tumours...
14 November 2022
Open Targets announced today that Genentech, a member of the Roche Group, has joined the consortium, which identifies, prioritises, and validates drug targets to accelerate the development of safe and effective medicines. The second company to join the industry-academic partnership this year, Genentech will collaborate with other consortium members including EMBL’s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.
26 May 2022
In a first-of-its-kind experiment, researchers have identified links between 127 genes and immune diseases, providing newfound insights into the sequence and timing of gene activity during the activation of T cells, a key process in regulating the body’s immune response.
The study, led by researchers from Open Targets, the Wellcome Sanger Institute and GSK, is published today (26 May 2022) in Nature Genetics. The result of a 3 year research effort, it is the first to show that nume...
14 February 2022
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success rate for developing new medicines. This complements the strengths of the five current partners: EMBL’s European Bio...
28 October 2021
Our locus-to-gene (L2G) machine learning scoring method was published in Nature Genetics (the preprint is also available). The L2G score reflects the likelihood that a gene is causal for the trait in question, allowing genes at trait-associated loci to be ranked by the relative strength of their evidence. It has been included in the Genetics portal since version 4.
30 June 2021
In our latest Genetics Portal release, we have integrated over 2,700 study endpoints from FinnGen, a public-private collaboration to identify genotype-phenotype correlations in the Finnish population. We have also integrated over 11,800 new studies from GWAS Catalog.
29 July 2020
Open Targets is excited to announce the release of our COVID-19 Target Prioritisation Tool, an interactive, open source web portal that integrates a number of key public datasets and publications to facilitate systematic exploration of host and viral targets as well as potential treatments for COVID-19.
6 June 2020
Open Targets is excited to announce that Gosia Trynka, our Experimental Science Director, has been awarded the 2020 Leena Peltonen prize by the European Society for Human Genetics (ESHG).
The prize is given every two years to an outstanding young researcher in the field of human genetics and it honours the memory of Dr. ...